

2025 ANNUAL REPORT

Momentum for Every Mind

Accelerating Progress Against Alzheimer's



UsAgainstAlzheimer's



Table of Contents

Annual Letter	2	Institutional Donor Spotlight	16
Who We Are	5	Financials	17
Brain Health For All	6	Events	19
Early Detection and Diagnosis	8	Thank You To Our Donors	21
Prevention and Risk Reduction	11	Gifts In Tribute	23
Making Every Voice Count	13	Ways to Give	24
Donor Spotlight	15	Boards of Directors 2025	26

Annual Letter

Dear Supporters, Partners, and Friends,

This year marks a pivotal moment in the fight to end Alzheimer's. For the first time, we're not just talking about breakthroughs—we're seeing them make a meaningful difference in people's lives.

After more than 100 years of research into Alzheimer's, we now have two disease-modifying treatments that can slow the progression of the disease. Researchers are now studying whether these treatments can also safely and effectively delay or reduce Alzheimer's symptoms before symptoms appear.

Growing evidence shows that prevention of up to half of Alzheimer's cases can be achieved through lifelong attention to brain health, including managing vascular health, diabetes, obesity, sleep disorders, and other behaviors within our control.

Individuals and families have more opportunities than ever to take action. None of this progress has been possible without all of **us**. That's why we named this organization UsAgainstAlzheimer's.

Your support is helping turn scientific discoveries into real-world impact, bringing hope to millions of families and moving us closer to achieving our mission: preventing Alzheimer's.

Our BrainGuide® has now reached more than **one million people**, giving people a simple, confidential way to assess memory concerns and take the next step toward prevention and care.

This year, we also launched the BrainGuide Clinical Trial Connector, making it easier for individuals, caregivers, and healthcare providers to find clinical trials and help speed up the path to better treatments.

This has also been a landmark year for early detection. The first FDA-approved blood tests for Alzheimer's have the potential to make diagnosis simpler, more accessible, and available earlier—bringing us closer to a future where treatment can begin sooner, when it matters most. Our corporate roundtable (the CEO Initiative on Alzheimer's, or CEOi) created recommendations for how these tests can be used. As a result, those tests are being rapidly embraced by clinicians, regulators, and companies. More than 3,500 clinicians attended CEOi educational sessions on this topic, and 70,000 visitors accessed our Alzheimer's Diagnostic Hub website.

At the same time, we remain committed to ensuring these advances reach everyone. Through a new public awareness campaign in Hispanic communities and our Brain Health Equity Nurse Fellowship, we are expanding access to trusted, culturally relevant brain health education and helping close longstanding gaps in diagnosis and care.


Prevention and risk reduction continue to be one of our greatest opportunities. Medicines designed to treat Alzheimer's before symptoms appear are now in testing. More and more evidence is emerging that healthy lifestyle choices can help protect brain health, thus empowering people to take action today.

We also know that scientific progress depends on sustained investment. That is why we launched United for Cures, the nation's first cross-disease patient advocacy coalition dedicated to protecting federal medical research funding.

Together with more than 60 partner organizations, we mobilized patients and advocates nationwide, delivering more than 108,000 letters and 56,000 calls to Congress, and helping secure a \$415 million increase for NIH research funding.

These efforts make certain that lifesaving discoveries continue moving from the laboratory to the people who need them. The momentum we are seeing today would have seemed unimaginable just a few years ago. But our work is far from finished. Together, we can make sure every breakthrough reaches every family, every community, and everyone at risk.

Thank you for believing in this mission and for making this progress possible. Because of you, we are moving closer to a future where Alzheimer's can be detected, prevented, and ultimately eradicated.



George Vradenburg

George Vradenburg

Chairman and Co-Founder
UsAgainstAlzheimer's

“

We don't wait
for progress.

**We create
momentum.”**





Who We Are

UsAgainstAlzheimer's is working to accelerate progress toward a world without Alzheimer's. We bring together government, industry, researchers, regulators, funders, people living with Alzheimer's, caregivers, and families to tackle some of the biggest challenges in Alzheimer's—and help ensure that advances in medicine and public health reach the people who need them most.

We don't wait for progress. We create momentum.

In 2025, UsAgainstAlzheimer's brought urgency, creativity, and bold leadership to advancing solutions in early detection, treatment access, prevention, and policy. We connected people and ideas, elevated the voices and experiences of those affected by Alzheimer's, and helped turn promising ideas into action.

Across our work, our focus remained clear: accelerate progress, expand access, and improve outcomes for every person and family affected by Alzheimer's.

Because progress matters most when it reaches everyone. And every mind deserves momentum.



Brain Health **for All**

Black and Latino Americans face significantly higher risks of dementia compared to white Americans. Women also continue to bear a disproportionate share of the burden, both as individuals living with Alzheimer's and as caregivers. Scientists are increasingly learning that Alzheimer's and related dementias may develop differently across populations, with distinct genetic, biological and life course risk factors, barriers to care, and health outcomes.

That's why advancing brain health for all has remained central to our mission from day one.

In 2025, UsAgainstAlzheimer's, supported in part by the Centers for Disease Control and Prevention (CDC), achieved important progress in outreach, education, and workforce development aimed at improving brain health outcomes in communities most affected by Alzheimer's.

Reaching Communities Most Affected by Alzheimer's

UsAgainstAlzheimer's continued leading targeted digital campaigns designed to raise awareness of brain health, reduce stigma, and promote risk reduction in Black and Latino communities. These campaigns connected individuals with trusted, culturally relevant resources through BrainGuide®, helping people take action to protect their brain health.

In 2025 alone, these efforts reached more than **1 million individuals**. Since launch, our outreach campaigns have connected with more than 3.3 million Black and Latino individuals nationwide.

Empowering Nurses as Community Health Leaders

UsAgainstAlzheimer's trains a new cohort of Brain Health Nurse Fellows each year, equipping nurses with specialized training and tools to serve as trusted messengers in their communities.

Since the Brain Health Equity Nurse Fellowship launched in 2022, **45 fellows** have completed the program, reaching thousands through community engagement and peer education.



In 2025, we expanded and strengthened the Fellowship program by:

- Piloting a curriculum based on the model with Mercy University School of Nursing, training 45 nurses in person
- Convening Fellowship alumni for a two-day workshop focused on storytelling and advocacy
- Launching a dedicated Fellowship microsite
- Presenting the Fellowship program at the annual conferences of the National Association of Hispanic Nurses and the National Black Nurses Association

Addressing disparities in brain health is not optional—it is essential to our mission of preventing Alzheimer's for everyone. Through sustained partnerships and evidence-based strategies, UsAgainstAlzheimer's is helping ensure every community has access to the knowledge, resources, and care needed to live healthier, longer lives.



Early Detection and Diagnosis

The Difference Early Detection Makes

Too often, Alzheimer's is diagnosed too late—or not at all. Early detection remains one of the greatest opportunities to improve access to treatment, care planning, and quality of life for individuals and families affected by the disease.

Early detection is critical because the two currently FDA-approved treatments for Alzheimer's work best when the disease is identified and treated earlier. Much like cancer and heart disease, detecting a disease in its earliest stages can lead to better outcomes, including the potential to slow disease progression.

As science advances, we are beginning to see what treatment could look like even earlier in the disease process; during the preclinical stage, when a person may have amyloid or tau changes in the brain, yet not experience noticeable changes in memory or brain function. As this research continues to emerge, early detection will become increasingly important, giving healthcare professionals the opportunity to identify Alzheimer's earlier and potentially intervene before significant symptoms develop.

BrainGuide®

BrainGuide® was created to help people better understand their brain health and take informed action. The free platform provides trusted, evidence-based resources and memory questionnaires in both English and Spanish, helping individuals recognize potential cognitive changes and seek care earlier.

In 2025, BrainGuide reached a major milestone, surpassing 1 million visitors nationwide. Approximately 500,000 individuals completed the platform's memory questionnaire, taking an important first step toward understanding their cognitive health.

Throughout the year, BrainGuide also expanded its capabilities by:

- Launching a clinical trial connector to help users explore research opportunities
- Advancing speech-based biomarker technology to support earlier and more accessible detection pathways
- Expanding culturally relevant outreach to communities at higher risk for Alzheimer's

Together, these advancements are helping more people move from concern to action earlier than ever before.

The Global CEO Initiative on Alzheimer's Disease (CEOi)

In 2025, the Global CEO Initiative on Alzheimer's Disease (CEOi), the corporate roundtable of UsAgainstAlzheimer's, continued to accelerate the development and adoption of innovative tools for earlier diagnosis and Alzheimer's prevention.

CEOi brought together global experts to establish consensus recommendations for using blood-based biomarkers and digital cognitive assessments in clinical practice—helping create clearer pathways to earlier, more accurate diagnosis.

Expanding education and driving impact, CEOi:

- Engaged more than **3,800** healthcare providers through virtual and in-person convenings
- Welcomed more than **70,000** visitors to its online educational resources
- Supported more than **20,000** users of its Diagnostic Database
- Published influential recommendations, including guidance on digital cognitive assessments in *Alzheimer's & Dementia*

CEOi also helped advance policies that can expand access to emerging diagnostic tools, including increased Medicare reimbursement for Alzheimer's blood tests and expanded coding pathways to support broader use.

Accelerating the Path to Therapeutic Intervention

CEOi also expanded its focus on accelerating therapies that could delay or prevent Alzheimer's. Bringing together researchers, advocates, clinical trial experts, regulators, and leaders from the COVID-19 vaccine development effort, CEOi developed a consensus-driven Target Product Profile to align the field around what successful Alzheimer's interventions should achieve.

Drawing lessons from one of the fastest-moving medical breakthroughs in recent history, the convening explored how the speed, collaboration, and innovation that transformed vaccine development could inform the future of Alzheimer's therapeutics.

Together, CEOi's efforts are helping build a future in which Alzheimer's is detected earlier, diagnosed more accurately, and addressed more proactively, bringing us closer to interventions that can change the trajectory of the disease.

Breaking Barriers to Treatment

In 2025, UsAgainstAlzheimer's continued advancing efforts to ensure safe and effective Alzheimer's treatments are accessible to everyone, especially those at highest risk.

In July, we convened a Food and Drug Administration (FDA) Patient Listening Session focused on ApoE4 homozygotes, individuals with increased genetic risk for Alzheimer's disease. More than 50 representatives from the FDA, National Institutes of Health (NIH), and the Reagan-Udall Foundation participated in discussions centered on patient experiences and emerging treatment considerations.

We also launched a multi-sector initiative focused on improving representation and diversity in Alzheimer's clinical trials to help ensure research reflects the populations most affected by the disease.

Advancing Inclusive Research and Care

In 2025, UsAgainstAlzheimer's:

- Convened leaders from industry, academia, community organizations, and health equity groups to establish more representative enrollment goals for Alzheimer's clinical trials
- Advanced publication of a manuscript documenting insights from the ApoE4 Patient Listening Session for *JAMA Neurology*
- Continued efforts to improve the inclusiveness and generalizability of Alzheimer's research and treatment development

Our work is helping ensure future Alzheimer's treatments are developed, tested, and delivered in ways that better reflect the diversity of individuals and families impacted by the disease.



Prevention and Risk Reduction

Prevention Starts with Us

At UsAgainstAlzheimer's, we envision a future where brain span equals lifespan.

In 2025, we continued advancing that vision by equipping healthcare professionals, employers, and communities with tools and evidence-based strategies to support lifelong brain health and reduce dementia risk.

Brain Health Academy™ (BHA)

Brain Health Academy™ (BHA) provides healthcare and wellness professionals with evidence-based education focused on reducing dementia risk and promoting brain health across the lifespan.

In 2025, BHA expanded its reach and infrastructure by:

- Launching a new Learning Management System
- Offering Continuing Medical Education (CME) credits in partnership with Rush University
- Establishing a Curriculum Advisory Committee to guide course development
- Launching seven new courses covering genetics, depression, obesity, menopause, biomarkers, screening, and vision loss

Since its launch, Brain Health Academy has:

- Developed **25 courses**
- Trained more than **14,000 healthcare and wellness professionals**
- Awarded more than **6,250 continuing education credits**

Participant feedback remained exceptionally strong, with 97% reporting that the content was current and 96% indicating it was directly relevant to their work.

After five successful years of advancing brain health education for healthcare professionals, BHA will conclude the development of new courses. While this marks the completion of our course offerings, the knowledge and evidence-based content developed through BHA will be repurposed and reutilized in other areas of our work.

We are exploring innovative ways to extend the impact of this valuable content by developing a free resource hub that makes practical, credible information on dementia risk reduction more widely available. These repurposed resources from BHA may include fact sheets, newsletters, implementation tools, and other materials designed to help healthcare professionals and the public translate research into action in an effort to support brain health for all.



Business Collaborative for Brain Health (BCBH)

The Business Collaborative for Brain Health (BCBH) continues bringing employers, investors, and innovators together to make brain health a workplace priority.

In 2025, BCBH:

- Convened more than 200 leaders in Houston, Texas, at a two-day series of roundtables to discuss the latest developments in brain health and develop recommendations for building an economy driven by brain capital. Helped launch Project Metis, an initiative positioning Houston as a global leader in brain health innovation
- Commissioned a HERO Health study examining workforce brain health and dementia-related economic risks
- Elevated brain health conversations at the United Nations General Assembly and World Economic Forum

These efforts are helping employers recognize that supporting brain health is not only good for people, but also critical for workforce resilience and long-term economic success.



Making **Every Voice Count**

Advancing the fight against Alzheimer's requires more than scientific discovery, it requires public policy that accelerates innovation and protects the research that makes breakthroughs possible.

In 2025, UsAgainstAlzheimer's continued to champion bipartisan policies that strengthen prevention, improve early diagnosis, expand access to care, and sustain federal investment in Alzheimer's research. We supported the bipartisan reintroduction of the Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act, helping build momentum for legislation that advances earlier detection and better care for people living with Alzheimer's.

As federal funding for medical research faced unprecedented threats, we also launched United for Cures, the nation's first coordinated, cross-disease patient advocacy coalition dedicated to protecting NIH-funded research. Together with more than 60 partner organizations, we mobilized patients, families, researchers, and advocates nationwide to ensure patients' voices were heard when critical funding decisions were being made.

Our collective advocacy helped protect NIH research funding, preserve essential research infrastructure, safeguard research grants, and secure a \$415 million increase for the NIH in the Fiscal Year 2026 Labor, Health and Human Services appropriations bill. Through coordinated advocacy efforts and grassroots engagement, we demonstrated the power of a united patient voice.

Together, these efforts are strengthening the foundation for future discoveries—bringing us closer to better treatments, better care, and ultimately, a world without Alzheimer's.

Advancing What Matters Most in Alzheimer's Disease

The Alzheimer's Disease Patient and Caregiver Engagement (AD PACE) initiative is a unique collaboration of patients, caregivers, nonprofit organizations, industry, researchers, and government partners working to redefine how success is measured in Alzheimer's disease. Through the What Matters Most™ (WMM) Research Program, AD PACE makes certain that the priorities and experiences of people living with Alzheimer's, and those who care for them, help shape future research, clinical trials, and treatment development.



In 2025, AD PACE completed data collection and analysis for the WMM survey, gathering insights from 640 participants across the Alzheimer's disease continuum, including people who are biomarker-positive but asymptomatic, those with mild cognitive impairment, people living with mild Alzheimer's disease, and caregivers of individuals with moderate to severe disease. More than 60% of participants identified as people of color, making this one of the most diverse studies of its kind. The findings identified important gaps between what people affected by Alzheimer's value most and what current clinical trial outcome measures assess, providing a roadmap for more patient-centered research and treatment evaluation.

The AD PACE initiative published its findings in *Alzheimer's & Dementia: Translational Research & Clinical Interventions*. It also presented research at five leading international scientific conferences, including the Alzheimer's Association International Conference (AAIC), ISPOR Europe, and Clinical Trials on Alzheimer's Disease (CTAD), helping advance patient-centered outcomes across the Alzheimer's research community.

Donor Spotlight



The Chalhoub Family

A Family's Commitment to Making a Difference

Like so many families, Walid and Hala Chalhoub have experienced the impact of Alzheimer's firsthand. Motivated by personal experience, they transformed their commitment into action through *Illuminating Hope*, an annual fundraising event supporting efforts to end Alzheimer's.

Their generosity has helped expand awareness, deepen community engagement, and provide critical support for families affected by Alzheimer's and other dementias.

We are deeply grateful for the Chalhoub family's leadership, compassion, and continued commitment to advancing hope for others.

Institutional Donor Spotlight



Eisai


Established in 1941, Eisai is a global pharmaceutical company committed to improving the lives of people affected by Alzheimer's disease. Guided by its human health care mission, Eisai continues advancing innovation in Alzheimer's research, diagnosis, and treatment.

UsAgainstAlzheimer's is grateful for Eisai's longstanding partnership and generous support, which has helped expand access to trusted brain health information and strengthen initiatives including BrainGuide®, the Brain Health Nurse Fellowship Program, and the National Alzheimer's Summit.

Together, we continue working toward a future with better outcomes for individuals and families affected by Alzheimer's.

<https://us.eisai.com/our-patient-focus>

Financials



The financial activity of UsAgainstAlzheimer's and UsAgainstAlzheimer's Action are audited collectively and combined for financial statement presentation purposes.

UsAgainstAlzheimer's holds a four-star rating from Charity Navigator's for our commitment to fiscal responsibility and transparency.

*Of the total combined expenses of nearly \$25.8 million, **91%** were spent on programmatic activities.*

UsAgainstAlzheimer's exceeds the minimum standard of 65% program expenses set by the BBB Wise Giving Alliance.

A complete copy of the financial statements audited by GRF CPAs and Advisors is available upon request by contacting stopalz@usagainstalzhimers.org

Combined Statement of Activities and Change in Net Assets for the Years Ended December 31, 2025, and 2024.

This statement provides a summary of the organization's revenue, expenses, and overall financial health, showing how its resources were used to advance its mission over the past two years.

REVENUE AND SUPPORT	2025	2024
Contributions and Grants	32,288,581	9,762,126
Special Events Revenue, Net of Expenses	428,569	289,567
Interest Income	390,748	384,044
Program Service Revenue	65,000	438,350
Other Revenue	30,870	22,481
Total Revenue and Support	33,203,768	10,896,568
EXPENSES		
Program Services	23,517,565	7,912,408
Support Services:		
Fundraising	1,263,639	1,084,681
Management and General	993,984	791,408
Total Supporting Services	2,257,623	1,876,089
Total expenses	25,775,188	9,788,497
CHANGE IN NET ASSETS	7,428,580	1,108,071
Net Assets at Beginning of Year	10,123,088	9,015,017
NET ASSETS AT END OF YEAR	17,551,668	10,123,088



Events

2025 National Alzheimer's Summit: From Personal Stories to Powerful Action



Each year, UsAgainstAlzheimer's convenes leaders across healthcare, science, government, industry, and the Alzheimer's community to accelerate progress and inspire action. Our 2025 National Alzheimer's Summit, *From Personal Stories to Powerful Action: Making a Difference in Alzheimer's*, brought together patients, caregivers, researchers, policymakers, and advocates to explore the latest advances in prevention, diagnosis, treatment, and care—while keeping the voices of those living with Alzheimer's at the center of every conversation.

The Summit featured powerful discussions on advancing science, reimagining diagnosis, and shaping policies that improve lives today while accelerating tomorrow's breakthroughs. Highlights included keynote conversations with UsAgainstAlzheimer's Co-Founder Meryl Comer and Emma Heming Willis, author and advocate, as well as Kim Campbell, founder of CareLiving.com. The event concluded with a fireside chat between Chairman and Co-Founder George Vradenburg and Rep. Linda Sánchez (CA), along with remarks from Rep. Gus Bilirakis (FL), underscoring the importance of bipartisan leadership in advancing Alzheimer's research, care, and innovation. The Summit's virtual reach continued to grow in 2025, reaching more than 16,000 web plays and more than 800,000 people through social media.

Third Annual Fall Fest for Alzheimer's

The Fall Fest for Alzheimer's has become an annual tradition dedicated to raising awareness about Alzheimer's disease, promoting brain health education, and inspiring our community to unite in support of the Alzheimer's movement. In 2025, The Leo Fund for Alzheimer's, founded by the Turgeon Family, hosted the event to raise awareness and funds, drawing over 300 guests and raising more than \$250,000.

The Turgeon Family established The Leo Fund for Alzheimer's because of a deeply personal connection. Like so many other families, they have experienced the devastating impact of this disease and are committed to helping other families facing the same journey. Building on the success of the first Fall Fest in 2023, this year's event not only raised significant funds but also spread crucial awareness about Alzheimer's disease and the need for continued research and support.



2025 Dunk Alzheimer's Basketball Tournament

Teenagers Natalie, Alex, and Max Veksler, with the help of their family, brought together kids and families for their annual three-on-three basketball tournament to raise money and awareness for Alzheimer's. The Veksler Family started Dunk Alzheimer's in 2019 to raise money and awareness for Alzheimer's disease. Since then, the event has raised nearly \$150,000 to support the UsAgainstAlzheimer's mission. In 2025, the Dunk Alzheimer's Basketball Tournament raised more than \$45,000 to support critical programs and advocacy on behalf of all those living with Alzheimer's and their families.



Thank You **to Our Donors**

UsAgainstAlzheimer's is grateful to the many generous donors whose philanthropy makes the work we do possible. In addition to the ongoing visionary support from our Founding Chairman, George Vradenburg, we are proud to recognize the following supporters to UsAgainstAlzheimer's, UsAgainstAlzheimer's Action and the United for Cures initiative:

\$1,000,000 or More

American Association for Advancement of Science
Anonymous (2)
Biogen, Inc.
Eisai, Inc.
Eli Lilly Co.
Open Philanthropy Action Fund
George A. Vradenburg

\$200,000 - \$999,999

Anonymous
Centers for Disease Control and Prevention
Ray and Dagmar Dolby Family Fund
Doris Duke Foundation
Janssen
Arlene and Robert Kogod
Novo Nordisk
Sanofi

\$100,000 - \$199,999

AC Immune
Act for NIH Foundation
Bristol Myers Squibb
Genentech
GN Hearing
Lyda Hill
Roche Diagnostics

\$50,000 - \$99,999

Acadia Pharmaceuticals Inc.
Beckman Coulter, Inc.
CaringKind
Epstein Family Foundation
F. Hoffmann-La Roche
Gates Ventures
GE Healthcare
Michael Glosserman
The Martha and Warren Halle Foundation
Paul Hogan
Lundbeck
Merck Sharp & Dohme
PhRMA
Quest Diagnostics
Rice University
Robert Wood Johnson Foundation
Royalty Pharma, LLC
The University of Texas Medical Branch

\$25,000 - \$49,999

AbbVie Inc.
Anavex Life Sciences
Blue Ash Partners
C2N Diagnostics
Cognito Therapeutics
Collis Warner Foundation
Meryl Comer
Ric and Jean Edelman
NeuroVision Imaging
Progressive Medical Concepts LLC
Prothena Biosciences
Ann Reed
Segal Family Foundation
Steelcase
Karen Tanz
Shawn Taylor/KPB Corporation
Volunteers of America
West Health Institute

\$10,000 - \$24,999

Advanced Medical Technology Assoc
The Alzheimer's Drug Discovery Foundation
Alzheimer's Foundation of America
Alzheon
Rita Allen Foundation
Danny and Cindy Anastasi
Anonymous (3)
Aspen Neuroscience, Inc.
Axsome Therapeutics, Inc.
Jaromir and Lynn Babicka
Bank of America
BrightFocus Foundation
Cure Alzheimers Fund
Easton Family Fund
Eleven Eleven Foundation
Shari and Michael Ellenbogen
Epic Systems
Federation of American Societies for Experimental Biology
Lynne Flexner
Fowler Family
Fraydun Foundation
Giving A Reason for Hope, Inc
Herson-Stirman Family Foundation
Candise Holmlund
Lauren and Glen Howard
Pamela Hu

Elizabeth Kessler
William and Linda Kirvan Family Foundation
La Costa Glen Carlsbad and The Glen at Scripps Ranch
Herbert J. and Dianne J. Lerner Foundation
Jill Lesser and Jonathan Diesenhaus
Kathleen and Chris Matthews
Mirador Therapeutics
Sandy and Jesse Morgan
Pathstone
The Prentice Foundation
Darrell and Marlene Rader
Eammon Reilly
Roger Sant
Donald and Sylvia Simon Fund
Sandra and Lawrence Small
Peter Smith
Masood Tayebi
Turgeon Family Foundation
Wendy Walker
Nancy and Harold Zirkin

\$5,000 - \$9,999

AARP
Alterwood Health Management Company
Alzheimer's Greater Los Angeles
Alzheimer's Orange County
American Diabetes Association
BetterBrain
Judy and Peter Blum Kovler Foundation
Dr. Philip and Faith Bobrow
Ann and Thomas Boyle
Breakthrough T1D
Brightview Senior Living
Toni and Dwight Bush
CAMD Critical Path Institute
Steve Cohen
Mark and Marcy Few
Margaret Ann Fowler
The Gerontological Society of America
Carol Brown Goldberg and Hank Goldberg
Guerrero Family Foundation
Nadim Haddad
High Lantern Group
HKS Inc
Hoiberg Charitable Fund
John A. Hartford Foundation
Heather Kaye

Richard and Ruth Lavine Family Foundation
 Timothy Lynch
 Lori McLeod
 Marlene Malek
 Matan Family Foundation
 Mayo Foundation For Medical Education
 and Research
 Meadows Mental Health Policy Institute
 Mario M. Morino Trust
 Robin and Henry Nordhoff
 Norm Ornstein and Judy Harris
 Joseph Perta
 James Pinto
 Harvey Sanders
 Amy Service-Salas
 Smoker Friendly
 Anne and Dennis Sullivan
 The Sulzberger Perpich Family Fund
 Synthesys Brain Health
 University of Texas at Dallas
 Scott Van Pelt
 Mary Katie Ward
 Carol and John Wilner

\$1,000 - \$4,999

American Association for Geriatric Psychiatry
 Abbott Laboratories
 ACC Mortgage
 Adfero
 Adler Family Foundation
 Kathy Alameda
 Hilary Alger and Chris Sanchirico
 Alliance for Aging Research
 Alliance for Patient Access
 Alzheimer's New Jersey
 Alzheimers San Diego
 Alzheimer's Tennessee, Inc.
 American Academy of Neurology
 American Society of Consultant Pharmacists
 Peter Angus
 Anonymous
 The Association For
 Frontotemporal Degeneration
 Bank Of America Charitable Foundation
 Banner Health
 Robert K. Barth
 Gail Bassin
 Sydney and Blake Bath
 Beltway Cleaning Services
 Ray and Nina Benton
 Bernstein Philanthropic Impact Fund
 Biotechnology Innovation Organization
 Kelli Borges
 Sara Boswell
 Chris Bowers
 Jim Breheny
 Patricia Brutton
 Scott and Kristi Bryan
 Mary Beth Busby
 Jane Caples
 Caregiver Action Network
 Chesapeake Finishing

Chevy Chase Acura
 CJD Foundation
 Pat Clancy
 CMDCC
 Anne Constant
 Constellation Brands, Inc.
 Creative Planning Foundation
 Jerry and Mary Cronin
 Estelle Cunningham
 DARCARS of Silver Spring
 Dementia Alliance of North Carolina
 Thuy Doan
 Sheryl Durkin
 John Dwyer and Susan Buckingham
 Envision Consulting
 Ruth Evans
 Pamela Farr
 Firestone Family Pay It Forward Fund
 Martha Blair FitzGerald
 Jeremy FitzGerald
 Brian Foist
 Elizabeth Frazee
 Joy Garrish
 Bradley and Sunny Goldberg
 Uschi Goldmann Crouch
 Stanley Goldstein
 Lulu Gonella
 Matthew Grandonico
 Greater Houston Golf Charity
 GRF CPAs & Advisors
 Hamadeh and Gerard Moawad Fund
 Helen Trybus Real Estate
 Marsha Henderson
 Hercules Fence
 Hilarity for Charity
 Lawrence and Carol Horn
 International Association for Indigenous Aging
 Jaklitsch Law Group
 Adam Joel
 Kristy Johnson
 Kelli Karches
 Brooks and Peter Kenny
 Kensington Park Senior Living
 KeyBank
 Bobbie and Bill Kilberg
 Linda Kirvan
 Klein Family Charitable Fund
 Elise Lefkowitz/Dorothy G. Bender Foundation
 Lewy Body Dementia Association, Inc.
 Sandy Liarakos
 LuMind Research Down Syndrome Foundation
 Robert Macmullin
 Managed Care Advisors
 Dilpriya Kaur Mangat
 Phillip Margolius
 Alex & Amanda Marshall
 Sheila McCoy
 Tim McGivern
 Joe and Lorna McMahon
 Margaret Meagher
 MeriTalk
 Kellee Mitchell

MJK Foundation
 Steve Montgomery
 Bridget and Shane Moore
 Morgan Stanley
 Katey Nalls
 Darrell and Patricia Nance
 Ann Napoletan
 Joan Nathan Gerson
 National Alliance For Caregiving, Inc.
 Susan Nettinga
 Noah Homes, Inc.
 Greg O'Brien
 Michael and Maria O'Brien
 Ohio Council for Cognitive Health
 Robert Osborne
 Nancy Palermo
 Partnership to Fight Chronic Disease
 Alan Perlmutter
 Perry Family of the Fund for Charitable Giving
 Ron Pirtle
 Laura Plank
 Ken Polk
 Lawrence & Carol Pollock Family Foundation
 Renay Regardie
 Diane Rehm and John Hagedorn
 Rob Reilly
 Lola Reinsch
 Ridgewells
 Rock Spring Contracting (Keegan & DeSarno)
 Peggy Saferstein
 David Satcher
 Lisa Schoelen Schwartz
 Second Wind Dreams, Inc.
 Karen Segal
 Mary and Bob Shue
 Felisse Sigurdson
 Kim and Alby Silvera
 Richard Silverman
 Meryl Silverman
 Douglas Simon
 Society for Women's Health Research
 Wendy Stewart
 Tina Stoll
 Thomas Rutherford Foundation
 Michael and Elizabeth Thompson Family Fund
 Tito's Vodka
 Ronald Treveloni
 UMMC Fund
 Karl Vauter
 William and Wendi Walsh Family Gift
 WANADA
 Alice Watkins
 Alex White
 David Wright

Gifts In Tribute

Special thanks to all those who have made gifts in honor and memory of mothers, fathers, grandparents, family members and caregivers. Gifts of \$50 or more were made in honor or memory of the following:

Johnnie Ali	Conrad L. Gooding	Thomas J. Prescott
Celeste Barone	Theresa Grant	Hellen S. Randolph
Ceil Berman	Felipe Gross	Patricia Conaghan Redmond
Shoshana Blauer	Susanne Graff Henderson	Mary Rehfield
Neil Buckholtz	Jack Hornfeldt	Jay Reinstein
Lillian Buckingham	James Earl Horell	Harvey Saferstein
Betty J. Carter	Lauren Howard	Red Scarff
Daniel E. Catullo	Cye Jacobson	Patricia B. Schwartz
Catherine McDonald	Sunja Choi Joel	Ernest Sobieski
Gerry Connolly	John R. Kleckner	E. Ruth Spiers
Lorenzo Cose	Magdalana Konrad	Dolores Steinhilber
Elizabeth Cox	Sandra Kosik	Shirley Szymanski
Peter J. Crossley	The Leo Fund	Lucia Townsend
Howard Crum	Robert Liggett	Lee Tull
Mary Davis	Yueh Chao Lin	Robert J. Turgeon
Barbara Dunne	Mary Lynch	Thomas Uhl
Richard Everman	Erich and Sara Marquardt	Sheila Vauter
Betty Fallot	Victoria Ebunoluwa Mason	Alex Veksler
Phyllis Fekete	Fred McIntyre	Francisco Javier Verdecia
Phyllis Sara Fern	Barbara McQueeney	Trish Vradenburg
Lou Fiore	Jean Marie Meeks	George Vradenburg
Kathy Forsberg	Ronald Mickler, Sr.	Joseph Randell Wall
Jon Riggs Fowler	Mona Miller	GoGo Willis
Frances Friedlein	Minnie Mittenhal	Morgan Wimbush
Jim Garner	James (Jim) Moore	Margaret Woolslayer
Saralyn Glen	Daniel Muller	Joe Don Yates
Michael Glosserman	Max Nissim	Rita Zalweski
Nancy B. Gofus	Ida Bell Pirtle	
George Goldstein	Nicole Pompy	

Ways to Give

Become a Member:

Become a Member of UsAgainstAlzheimer's for as little as \$25 per year. You can choose the membership plan that's right for you. Each level comes with exclusive benefits to help you deepen your relationship and your impact:

Membership Levels		
MEMBER With a gift of \$25 or more, you'll receive: • Our quarterly newsletter • Our printable Annual Report • First look at breaking news \$25 or more annually	ALLY With a gift of \$100 or more, you'll receive: • Our quarterly newsletter • Our printable Annual Report • First look at breaking news • Exclusive invitations to Leadership Briefings • Shareable social media photo frames \$100 or more annually	CHAMPION With a gift of \$25 or more, you'll receive: • Our quarterly newsletter • Our printable Annual Report • First look at breaking news • Preferred Access to virtual and in-person events • Exclusive invitations to Leadership Briefings • Shareable social media photo frames \$25 or more per month

Visit: <https://www.usagainstalzhimers.org/join-us>

Donate by Mail:

You can send a check to UsAgainstAlzheimers at the following address:

UsAgainstAlzheimer's
5614 Connecticut Avenue NW, #288
Washington, DC 20015

Gifts of Stock and Securities:

Donating stock or securities is a great way to make a contribution while receiving potential tax benefits. You could earn a charitable deduction for the full fair market value of publicly traded stock or securities and avoid capital gains taxes on securities that have increased in value, provided you have owned them for one year. For more information, or to notify of us a pending transfer, please contact Anne Adams at aadams@usagainstalzheimers.org

ACH/Wire Instruction for Cash Transfers:

If you would like to make a gift using direct, electronic transfer by wire or ACH, please contact Anne Adams for routing instructions at aadams@usagainstalzheimers.org

Donor Advised Funds:

You can initiate a grant recommendation from your donor-advised fund – or DAF – directly to UsAgainstAlzheimer’s. Contact your Donor Advised Fund administrator and recommend a grant directly to UsAgainstAlzheimer’s, using the following information:

**5614 Connecticut Avenue NW, #288
Washington, DC 20015
Tax ID#: 45-0672514**

Matching Gifts

Will your employer match your gift? Many companies offer matching gift programs and will match charitable contributions or volunteer service by their employees. To find out if your company has a matching gift policy, contact your Human Resources department.

Creating a Legacy Through Planned Giving

Remembering UsAgainstAlzheimer’s in your will is a powerful way to leave a meaningful legacy for people living with Alzheimer’s and may also have tax benefits. You can also leave a legacy by naming UsAgainstAlzheimer’s as beneficiary of a life insurance policy or a retirement plan (such as IRA or 401(k) plan). Of course, your personal financial situation is unique, so you should be sure to talk to your financial or legal advisor before making a request or creating a legacy. Please reach out to Anne Adams at aadams@usagainstalzheimers.org to learn more.

Boards of **Directors** 2025

UsAgainstAlzheimer's 501(c)(3)

Chairman, George Vradenburg

Founding Board Member

Co-Founder & Chairman, UsAgainstAlzheimer's

Treasurer, Shawn Taylor

Founding Board Member

Trustee, KPB Corporation

Secretary, Karen Segal

Board Member

Founding Board Member,
Children's Research Fund North
Suburban Board of Ann & Robert H.
Lurie Children's Hospital of Chicago

Meryl Comer

Founding Board Member

Vice Chairperson, Women's Health
Access Matters

John Dwyer

Founding Board Member

President, GAP Foundation

Karin Hellsvik

Board Member

VP Corporate Affairs & IR, Foghorn Therapeutics

Paul Hogan

Board Member

Founder Home Instead Senior Care

Greg O'Brien

Board Member

Journalist; Author, *On Pluto*

UsAgainstAlzheimer's Action 501(c)(4)

Chairman, George Vradenburg

Founding Board Member

Co-Founder & Chairman, UsAgainstAlzheimer's Action

Secretary/Treasurer, Jill Lesser

Founding Board Member

President, WomenAgainstAlzheimer's
Principal, JAL Consulting, LLC

Strategic Consultant, Nancy M. Zirkin

Board Member

Emeritus Board Member

David Satcher, MD, PhD, Former U.S. Surgeon
General

Founding Director, Satcher Health Leadership Institute,
Morehouse School of Medicine

Stanley Prusiner, MD, *Founding Board Member*

Professor, Univ. of California, San Francisco

In Memoriam Board Members

Trish Vradenburg, *Founding Board Member*

Co-Founder & Vice President, UsAgainstAlzheimer's &
UsAgainstAlzheimer's Action

Marilyn Glosserman, Co-Founder, Marilyn & Michael
Glosserman Community Foundation

UsAgainstAlzheimer's

 www.usagainstalzhaimers.org

 202-410-5199

 UsAgainstAlz

 @UsAgainstAlz

 @usagainstalz